We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Intellia Therapeutics Inc (NTLA) USD0.0001

Sell:$11.76 Buy:$11.79 Change: $0.34 (2.81%)
NASDAQ:2.19%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$11.76
Buy:$11.79
Change: $0.34 (2.81%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$11.76
Buy:$11.79
Change: $0.34 (2.81%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Contact details

Address:
40 Erie St Ste 130
CAMBRIDGE
02139-4254
United States
Telephone:
+1 (857) 2856200
Website:
https://www.intelliatx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NTLA
ISIN:
US45826J1051
Market cap:
$1.22 billion
Shares in issue:
101.80 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • John Leonard
    President, Chief Executive Officer, Director
  • Edward Dulac
    Chief Financial Officer, Executive Vice President, Treasurer and Principal Financial Officer
  • Eliana Clark
    Executive Vice President, Chief Technology Officer
  • Laura Sepp-Lorenzino
    Executive Vice President, Chief Scientific Officer
  • James Basta
    Executive Vice President, General Counsel, Corporate Secretary
  • Derek Hicks
    Executive Vice President, Chief Business Officer
  • David Lebwohl
    Executive Vice President, Chief Medical Officer
  • Michael Dube
    Chief Accounting Officer, Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.